The level of matrix metalloproteinase type 12 in the blood of arterial hypertension patients with high cardiovascular risk on the background of statin therapy

Abstract

Objective: to evaluate the features of changes in the content of metalloproteinase-12 (MMR-12) in blood serum in patients with arterial hypertension (AH) of high cardiovascular risk (SSR) against the background of therapy with atorvastatin (20 mg/day) or rosuvastatin (10 mg/day; 20 mg/day; 40 mg / day) as part of complex therapy. Materials and methods. The study included 140 patients with stage II hypertension, with partially controlled BP, the duration of the disease is 5-12 years, who, against the background of hypotensive therapy (enalapril 20-40 mg/ day, indapamide retard 1.5 mg, metoprolol 100-150 mg/day) received atorvastatin (Liprimar) 20 mg/day for 1 year, subsequently, it was replaced with rosuvastatin (Rosucard)10, 20, 40 mg / day. The dose regimen was determined by achieving the target level of low-density lipoprotein cholesterol (LDL) and cholesterol (HC). Results. During atorvastatin therapy, the content of MMR-12 in each of the three groups did not change. In the group of patients taking rosuvastatin 10 mg / day, the content of MMP-12 did not change for 18 months In the group of patients taking rosuvastine 20 mg / day, a decrease in MMP-12 was observed only by 12 months of therapy - by 26.8%, by 18 months - by 30.4% (p<0.05) When taking rosuvastine 40 mg / day, a decrease in MMP-12 was observed by 24.1% by 6 months, by 12 months - by 35.3%, by 18 months - by 37.1% (p<0.05). Conclusion. In patients with hypertension with high SSR, rosuvastatin as part of a complex therapy had an ambiguous effect on the content of MMR-12 in the blood, the greatest decrease in the level of MMR-12 was registered when taking 40 mg / day of rosuvastatin.